Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Stephen Bloch sold 25,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $79.47, for a total transaction of $1,986,750.00. Following the transaction, the director owned 855,073 shares of the company’s stock, valued at $67,952,651.31. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Liquidia Price Performance
Liquidia stock opened at $79.47 on Thursday. Liquidia Corporation has a 52 week low of $12.88 and a 52 week high of $82.96. The business has a 50-day simple moving average of $63.33 and a 200 day simple moving average of $46.35. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The stock has a market cap of $7.07 billion, a price-to-earnings ratio of 567.68 and a beta of 0.55.
Liquidia (NASDAQ:LQDA – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, research analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Liquidia
Institutional Trading of Liquidia
Several hedge funds have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia in the 4th quarter valued at about $25,000. Covestor Ltd grew its position in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Liquidia during the 3rd quarter worth approximately $34,000. NewEdge Advisors LLC bought a new position in Liquidia during the 2nd quarter worth approximately $25,000. Finally, Hurley Capital LLC increased its stake in Liquidia by 140.7% in the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock worth $179,000 after purchasing an additional 3,040 shares during the period. 64.54% of the stock is owned by institutional investors.
About Liquidia
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Read More
- Five stocks we like better than Liquidia
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
